tbuckley/cabot-search huggingface dataset:
Improving outcomes of first‐episode psychosis: an overview
Authors: Paolo Fusar‐Poli, Patrick D. McGorry, John M. Kane
Journal: World Psychiatry (2017)

Outcomes of psychotic disorders are associated with high personal, familiar, societal and clinical burden. There is thus an urgent clinical and societal need for improving those outcomes. Recent advances in research knowledge have opened new opportunities for ameliorating outcomes of psychosis during its early clinical stages. This paper critically reviews these opportunities, summarizing the state‐of‐the‐art knowledge and focusing on recent discoveries and future avenues for first episode research and clinical interventions. Candidate targets for primary universal prevention of psychosis at the population level are discussed. Potentials offered by primary selective prevention in asymptomatic subgroups (stage 0) are presented. Achievements of primary selected prevention in individuals at clinical high risk for psychosis (stage 1) are summarized, along with challenges and limitations of its implementation in clinical practice. Early intervention and secondary prevention strategies at the time of a first episode of psychosis (stage 2) are critically discussed, with a particular focus on minimizing the duration of untreated psychosis, improving treatment response, increasing patients’ satisfaction with treatment, reducing illicit substance abuse and preventing relapses. Early intervention and tertiary prevention strategies at the time of an incomplete recovery (stage 3) are further discussed, in particular with respect to addressing treatment resistance, improving well‐being and social skills with reduction of burden on the family, treatment of comorbid substance use, and prevention of multiple relapses and disease progression. In conclusion, to improve outcomes of a complex, heterogeneous syndrome such as psychosis, it is necessary to globally adopt complex models integrating a clinical staging framework and coordinated specialty care programmes that offer pre‐emptive interventions to high‐risk groups identified across the early stages of the disorder. Only a systematic implementation of these models of care in the national health care systems will render these strategies accessible to the 23 million people worldwide suffering from the most severe psychiatric disorders.
SCIT-treatment With a Chemically Modified, Aluminum Hydroxide Adsorbed Peanut Extract (HAL-MPE1) Was Generally Safe And Well Tolerated And Showed Immunological Changes In Peanut Allergic Patients
Authors: Carsten Bindslev-Jensen, Pieter-Jan de Kam, Esther van Twuijver, Diderik Boot Boot, Rachid El Galta, Anja Pahlow Mose, Line Kring Tannert, Dirk-Jan Opstelten
Journal: Journal of Allergy and Clinical Immunology (2017)
Impact of Young and Strong on physical activity in young breast cancer survivors.
Authors: Jennifer A. Ligibel, William Thomas Barry, Kathryn Jean Ruddy, Mary Greaney, Shoshana M. Rosenberg, Kim Sprunck-Harrild, Evan Morgan, Sarah Walsh, Karen Emmons, Ann H. Partridge
Journal: Journal of Clinical Oncology (2016)

175 Background: Inactivity is common in breast cancer survivors and has been linked to poor outcomes. Few trials have tested physical activity (PA) interventions in young women with breast cancer, who may face unique PA barriers due to demands of jobs and young families. Methods: Young and Strong was a cluster-randomized study evaluating the effect of education interventions for young breast cancer survivors.Sites were randomized 1:1 to a young women’s intervention (YWI), focused on fertility and other issues facing young women, or to a physical activity intervention (PAI). At PAI sites, providers were instructed to discuss PA with patients, and participants were given materials to encourage PA. PA was measured with the modified Godin Leisure Score Index at baseline, and 3, 6, and 12 months. Medical records were reviewed to assess provider attention to PA. Changes in weekly min of PA were compared between the PAI and YWI groups using general estimating equations to evaluate clustered binary and Gaussian data. Results: 467 patients enrolled between 7/12 -12/13 across 54 sites. Median age at dx was 40yrs (range 22-45). At baseline, participants were moderately active. PA increased in both groups over time (Table); there was no significant difference in PA between groups at any time (all p &gt; 0.1). Provider attention to PA was documented in 74% of participants on PAI and 61% on YWI (p = 0.15), and correlated with PA at 12 months (median 100 min/wk of PA in participants with provider attention to PA vs. 60 min/wk in those without, p = 0.016). Participants who reported reading all or most the PAI materials reported higher levels of PA vs. those who read less (78% vs. 64%, p = 0.05) Conclusions: Young breast cancer survivors assigned to a PA intervention did not increase PA more than those assigned to an intervention focused on young women’s issues. However, the higher levels of PA among women who engaged with the PAI materials and those whose oncology providers addressed PA suggests the importance of enhancing patient and provider engagement with healthy lifestyle information and recommendations. Clinical trial information: NCT01647607. [Table: see text]
Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).
Authors: Christine I. Chen, Darrell White, C. Tom Kouroukis, A. Keith Stewart, Kang Howson-Jan, Loree Larratt, Jean Powers, Elizabeth Eisenhauer
Journal: Blood (2004)
Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study
Authors: Olivier Casasnovas, Pauline Brice, Reda Bouabdallah, Gilles A. Salles, Aspasia Stamatoullas, Jehan Dupuis, Oumedaly Reman, Thomas Gastinne, Bertrand Joly, Krimo Bouabdallah, Emmanuelle Nicolas-Virelizier, Serge Bologna, Franck Morschhauser, Richard Delarue, Hassan Farhat, Philippe Quittet, Alina Berriolo-Riedinger, Adrian Tempescul, Véronique Edeline, Herve Maisonneuve, Jean Claude Eisenmann, Alexandra Traverse-Glehen, Marc Andre, Nicolas Mounier, Michel Meignan, Christophe Fermé
Journal: Blood (2015)
Annals Story Slam - Voiceless in Philadelphia
Authors: David Cognetti
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 February 2017Annals On Being a Doctor Story Slam - Voiceless in PhiladelphiaFREEDavid Cognetti, MDDavid Cognetti, MDFrom Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0014 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Voiceless in Philadelphia "Voiceless in Philadelphia," by David Cognetti, MD (Duration 6:31)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.Current Author Address: David Cognetti, MD, Thomas Jefferson University Hospital, Philadelphia, PA; e-mail, David.[email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 February 2017Volume 166, Issue 3Page: SS1 ePublished: 7 February 2017 Issue Published: 7 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...
Central Nervous System (CNS) Relapse in Extranodal NK/T Cell Lymphoma, Nasal Type: When Do We Need CNS Prophylaxis in Patients with Extranodal NK/T Cell Lymphoma?
Authors: Seok Jin Kim, Sung Hyun Kim, Jooryung Huh, Young-Hyeh Ko, Hyo-Jin Kim, Cheolwon Suh, Won Seog Kim
Journal: Blood (2008)
Study of Mechanisms Underlying Fetal Transplantation Tolerance: Relative Organ Distribution of B Cells and CD45 Isoform Expression Patterns.
Authors: Jessica L. Skopal-Chase, John S. Pixley, Anupama S. Bhat, Alireza Torabi, Nicole M. Aiazzi, David S. Thain, Esmail D. Zanjani
Journal: Blood (2006)
Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and Repair
Authors: Malte Tiburcy, James E. Hudson, Paul Balfanz, Susanne Schlick, Tim Meyer, Mei-Ling Chang Liao, Elif Levent, Farah Raad, Sebastian Zeidler, Edgar Wingender, Johannes Riegler, Mouer Wang, Joseph D. Gold, Izhak Kehat, Erich Wettwer, Ursula Ravens, Pieterjan Dierickx, Linda W. van Laake, Marie Jose Goumans, Sara Khadjeh, Karl Toischer, Gerd Hasenfuss, Larry A. Couture, Andreas Unger, Wolfgang A. Linke, Toshiyuki Araki, Benjamin Neel, Gordon Keller, Lior Gepstein, Joseph C. Wu, Wolfram-Hubertus Zimmermann
Journal: Circulation (2017)

Background: Advancing structural and functional maturation of stem cell–derived cardiomyocytes remains a key challenge for applications in disease modeling, drug screening, and heart repair. Here, we sought to advance cardiomyocyte maturation in engineered human myocardium (EHM) toward an adult phenotype under defined conditions. Methods: We systematically investigated cell composition, matrix, and media conditions to generate EHM from embryonic and induced pluripotent stem cell–derived cardiomyocytes and fibroblasts with organotypic functionality under serum-free conditions. We used morphological, functional, and transcriptome analyses to benchmark maturation of EHM. Results: EHM demonstrated important structural and functional properties of postnatal myocardium, including: (1) rod-shaped cardiomyocytes with M bands assembled as a functional syncytium; (2) systolic twitch forces at a similar level as observed in bona fide postnatal myocardium; (3) a positive force-frequency response; (4) inotropic responses to β-adrenergic stimulation mediated via canonical β 1 - and β 2 -adrenoceptor signaling pathways; and (5) evidence for advanced molecular maturation by transcriptome profiling. EHM responded to chronic catecholamine toxicity with contractile dysfunction, cardiomyocyte hypertrophy, cardiomyocyte death, and N-terminal pro B-type natriuretic peptide release; all are classical hallmarks of heart failure. In addition, we demonstrate the scalability of EHM according to anticipated clinical demands for cardiac repair. Conclusions: We provide proof-of-concept for a universally applicable technology for the engineering of macroscale human myocardium for disease modeling and heart repair from embryonic and induced pluripotent stem cell–derived cardiomyocytes under defined, serum-free conditions.
Effective Telomerase Inhibition Via Expression of Dominant-Negative HTERT Leads to Altered Growth Kinetics, Elevated Apoptosis and Increased Radiosensitivity of Bcr-Abl-Positive K562 Cells In Vitro.
Authors: Ute Brassat, Stefan Balabanov, Henning Wege, Daniel Roessler, Kerstin Borgmann, Tim Brummendorf
Journal: Blood (2007)
Anti-HLA Antibodies and Graft Rejection In Hematopoietic Stem Cell Transplantation
Authors: Stefan O. Ciurea, Fleur Aung, Marcos de Lima, Peter F. Thall, Gabriela Rondon, Partow Kebriaei, Amin Alousi, Elizabeth J. Shpall, Chitra Hosing, Issa F Khouri, Richard E. Champlin, Marcelo Fernandez-Vina
Journal: Blood (2010)
EPID-03. ARE THERE RACIAL AND AGE RELATED DIFFERENCES IN NON-MALIGNANT BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR INCIDENCE IN THE UNITED STATES?
Authors: Haley Gittleman, Quinn Ostrom, Carol Kruchko, Jill Barnholtz-Sloan
Journal: Neuro-Oncology (2016)

The Central Brain Tumor Registry of the United States (CBTRUS) contains the largest aggregation of population-based data on the incidence of primary brain and central nervous system (CNS) tumors in the US. CBTRUS data from 2006 to 2013 were used to determine the incidence of common non-malignant tumors by race, including whites, blacks, American Indian/Alaska Natives (AIAN), and Asian/Pacific Islanders (API), and age group, including those age 0-14 years, 15-39 years, and 40 years and older. Age-adjusted incidence rate ratios (IRR) per 100,000 population and 95% confidence intervals (CI) were calculated for selected non-malignant brain and CNS tumors overall and by race, stratified by age group. In age 0-14 years, incidence of neuronal and mixed neuronal glial tumors was lower in blacks (IRR: 0.64), AIAN (IRR: 0.36), and API (IRR: 0.86) as compared to whites. Incidence of nerve sheath tumors was lower in blacks (IRR: 0.89) and AIAN (IRR: 0.75) but higher in API (IRR: 1.25) as compared to whites. In age 15-39 years, incidence of pituitary tumors was lower in AIAN (IRR: 0.83) but higher in blacks (IRR: 1.23) and API (IRR: 1.13) as compared to whites. Incidence of grade I meningioma was lower in AIAN (IRR: 0.69) and API (IRR: 0.81) but higher in blacks (IRR: 1.16) as compared to whites. In age 40 years and older, incidence of grade I meningioma was lower in AIAN (IRR: 0.67) but higher in blacks (IRR: 1.21) and API (IRR: 1.05) as compared to whites. Incidence of pituitary tumors was lower in AIAN (IRR: 0.87) but higher in blacks (2.10) and API (IRR: 1.27) as compared to whites. The incidence of non-malignant brain and CNS tumors differs significantly by race and age in the US. Particularly, Grade I meningioma was consistently higher in blacks than in whites.
OS1.6 Tumor Microtubes contribute to resistance against surgical lesions, and chemotherapy in malignant glioma
Authors: S. Weil, M. Osswald, G. Solecki, J. Blaes, M. Gömmel, W. Wick, F. Winkler
Journal: Neuro-Oncology (2016)

AbstractBackground:The current standard for the treatment of astrocytomas, including glioblastomas, consists of tumor resection, followed by radio- and chemotherapy. As we could recently demonstrate, a dense multicellular tumor network formed by intercellular tumor microtubes (TMs) greatly contributes to radioresistance. The neuronal growth-associated protein 43 (GAP-43) is involved in this mechanism. Here we asked whether similar resistance mechanisms can be found with respect to surgical lesions, and chemotherapy.Methods:Cranial windows were implanted into 8–10 weeks old male NMRI nude mice. Human glioblastoma stem-like cells (GBMSCs; stably transduced with GFP, RFP, YFP, shRNA for GAP-43, control vector, and/or H2B-GFP to label tumor cell nuclei) were stereotactically injected into the mouse’s brain. In established tumors, 100mg/kg temozolomide (TMZ) was applied to mice p.o. for three consecutive days (day 0,1,2). For surgical lesion experiments, a regional injury was set to the brain by a 26 gauge Hamilton syringe.Results:Similar to radiotherapy, GBMSCs that were not part of the TM-connected tumor cell network died in relevant numbers 7 days after chemotherapy, while TM-connected tumor cells survived. The number of TM-connected tumor cells even increased twofold after chemotherapy, which speaks for an adapative resistance mechanism. It is currently under investigation whether knock down of GAP-43 increases overall efficacy of TMZ therapy. After surgical resection, the lesioned area was rapidly re-colonized with TM-extending tumor cells, with a striking increase in tumor cells at the site of lesion that by far extended the tumor cell densitiy in unlesioned tumor areas. Qantification revealed that the tumor cell nuclear density increased to numbers five-fold above values before surfical intervention in this area, evident as early as five days (488.3%; P=0.033; 95% CI, 50.3–726.4), and extending to 14 days (523.9%; P=0.03; 95% CI, 66.7–781.1) after surgical procedure. This apparent,,repair response” gradually diminished with increasing distance to the surgical lesion site. Finally, while dexamethasone did not relevantly change these reponses, GAP-43 knock down reduced them significantly.Conclusion:TMs convey primary and adaptive resistance to TMZ chemotherapy, in accordance to what we have shown before for radiotherapy. They are also involved in a strong repair response at the very site of a surgical lesion. Reducing the ability of gliomas to repair themselves, and to resist genotoxic stress by interfering with TM formation and function appears as a promising avenue to improve treatment efficacies in these callenging diseases.
Placenta Growth Factor Links the IL-13 Response and the Leukotriene Pathway to Augment Airway Hyper-Responsiveness
Authors: Marthe-Sandrine Eiymo Mwa Mpollo, Eric Brandt, Shiva Kumar Shanmukhappa, Paritha Arumugam, Swati Tiwari, Anastacia Loberg, Tilat Rizvi, Mark Lindsey, Bart Jonckx, Peter Carmeliet, Vijay Kalra, Timothy Lecras, Nancy Ratner, Marsha wills-Karp, Gurjit Khurana hershey, Punam Malik
Journal: Blood (2015)
Statin Use and Risk of Non-Hodgkin Lymphoma (NHL): Preliminary Results from the Mayo Clinic Case-Control Study.
Authors: James R. Cerhan, Zachary S. Fredericksen, Mark Liebow, Neil E. Kay, Thomas E. Witzig, Timothy G. Call, Ahmet Dogan, Kay M. Ristow, Alice H. Wang, Susan L. Slager, Thomas M. Habermann
Journal: Blood (2007)
Reduced Intensity Conditioning In Children Undergoing Unrelated Umbilical Cord Blood Transplantation for Non-Malignant Diseases: Preliminary Results Demonstrate a High Rate of Engraftment and Low Incidence of Gvhd
Authors: Suhag H Parikh, Paul L Martin, Timothy A Driscoll, Jennifer Baker, Ketti Piersol, Jerelyn Moffet, Andre Stokhuyzen, Joanne Kurtzberg, Paul Szabolcs
Journal: Blood (2010)
Investigation of Peanut-Specific T Effector (Teff) and T Regulatory (Treg) Cells in the Blood of Allergic and Non-Allergic Individuals
Authors: Katherine Weissler, Marjohn Rasooly, Daly Cantave, Hyejeong Bolan, Pamela A. Frischmeyer-Guerrerio
Journal: Journal of Allergy and Clinical Immunology (2017)

Peanut allergy is potentially life-threatening and generally has a poor prognosis. Recent data suggests the skin may be an important route of initial sensitization to peanut, and that early oral exposure to peanut is protective. In mice, Tregs are central to the development of tolerance to food, although definitive data in humans is lacking. We sought to quantify and phenotype peanut-specific Teffs and Tregs in individuals with and without peanut allergy. Whole blood was obtained from peanut allergic and non-sensitized/non-allergic individuals and stimulated with crude peanut extract or media alone. Peanut-specific Teffs and Tregs were identified based on upregulation of CD154 (CD40L) or CD137 (4-1BB), respectively. Flow cytometry was used to evaluate expression of cytokines and homing receptors. Differential upregulation of CD154 and CD137 efficiently distinguished peanut-specific Tregs (>90% Foxp3+) and T effs (<10% Foxp3+). Peanut-reactive Tregs did not produce cytokine and were found at a similar or greater frequency in the blood of peanut allergic individuals compared to non-allergic controls. Peanut-specific Teffs from allergic individuals produced predominantly IL-13 to peanut while non-allergic subjects expressed mostly IFN-γ. No significant difference in expression of skin (CLA) homing receptors on peanut-specific T cells was identified, although greater numbers of peanut-specific Teffs expressed gut (α4β7) homing receptors in allergic versus non-allergic individuals. Established peanut allergy is not associated with a deficiency in or altered homing of peanut-specific Tregs in the blood. Peanut-specific Teff cells are Th2- rather than Th1-skewed in peanut allergic subjects, and may be more likely to traffic to the gut.
Therapeutic Comparision of Surgical Resection Followed by R-CHOP and R-CHOP Alone for Primary Localized Intestinal Diffuse Large B Cell Lymphoma
Authors: Ho Sup Lee, Lee Chun Park, Eun Mi Lee, Seong Hoon Shin, Byeong Jin Ye, Sung Yong Oh, Moo-kon Song, Sang Min Lee, Won-Sik Lee, Byung Woog Kang, Myung Hee Chang, Seok-Goo Cho, Seung-Ah Yahng, Sung-Soo Yoon, Ji-Hyun Kwon, Yang Soo Kim
Journal: Blood (2011)
Injection of Blastocysts from Immunocompetent Mice with Human HPC Having High ALDH Activity Results in Chimeric Animals with Low-Level Human Contribution in Hematopoietic and Non-Hematopoietic Tissues.
Authors: Cynthia R. Giver, Sandra J. Foster, William D. Martin, Andrew E. Balber, Ned Waller
Journal: Blood (2004)
Lumiliximab Triggers Apoptosis Mechanisms in CLL Cells through the Inhibition of PI3-K/Akt Pathway.
Authors: Medhat Shehata, Susanne Schnabl, Elena Ponath, Stefanie Tauber, Dita Demirtas, Martin Hilgarth, Martin Bilban, Sigrun Badrnya, Karin Fleiss, Josef D. Schwarzmeier, Alexander Gaiger, Rainer Hubmann, Christoph C Zielinski, Steve Hughes, Ann Maclaren, Ulrich Jaeger
Journal: Blood (2009)
Behavior of breast cancer in young women: A Surveillance Epidemiology and End Results (SEER) database review.
Authors: Anteneh A. Tesfaye, Mohammad Mozayen, Ioana Morariu, David S. Eilender
Journal: Journal of Clinical Oncology (2012)

6 Background: Advanced age is a major risk factor for breast cancer in women. Small sized studies have reported variable outcome of breast cancer in young women. Our study was done to evaluate tumor characteristic and cancer specific survival among young women. Methods: The 1973-2009 SEER database was reviewed for women with breast cancer diagnosed between 2004 and 2009. Patients were grouped by age into: A (≤35 years), B (36-50 years) and C (&gt;50 years). Age, ethnicity, staging, lymph nodes status, micrometastasis in negative lymph nodes, tumor size, tumor grade, hormone receptor status were extracted. Data and survival were analyzed using chi square, Kaplan-Meier, Life table, and Cox proportional hazard model. The primary outcome was 5-year cancer-specific survival. Results: A total of 248,280 patients were included in the study, group A, B and C making 2.8%, 25.5% and 71.7% of study subjects respectively. The median tumor size was 2.4, 1.9, and 1.6 cm in groups A, B and C respectively (p=0.0001). Positive lymph nodes were seen in 52.5%, 43% and 34% in groups A, B and C respectively (p=0.0001). Regional disease was seen in 47.5%, 39.5% and 29.9% in groups A, B and C respectively (p=0.0001). Higher Grade histology was seen in 63.5%, 44.3% and 33.8% in groups A, B and C respectively (p=0.0001). ER-PR negative were found in 42.1%,26.4%, 22.6% of Groups A, B and C respectively (p=0.0001). Five year cancer specific survival was 82%, 89%, 86% in groups A, B and C respectively (p=0.0001). Independent prognostic factors are given in the table. Conclusions: Breast cancer is uncommon among young women (age &lt;35). Compared to other age groups, breast cancer in young women presents with bigger tumor, higher nodal positivity, an advanced stage, higher tumor grade, higher hormone receptor negativity, and worse 5-year cancer-specific survival. [Table: see text]
333O Post-transplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in diffuse large B cell lymphoma
Authors: Z. Ying, X. Wang, Y. Zhang, Y. Song, W. Zheng, X. Wang, Y. Xie, N. Lin, M. Tu, C. Zhang, L. Ping, W. Liu, L. Deng, J. Zhu
Journal: Annals of Oncology (2016)
Exhaled Nitric Oxide Concentration Measured By NO Breath® Correlate with Asthma Severity
Authors: Yosuke Kamide, Takahiro Tsuburai, Yuto Nakamura, Kentaro Watai, Yuto Hamada, Yasuhiro Tomita, Chihiro Mitsui, Hiroaki Hayashi, Kiyoshi Sekiya, Yuma Fukutomi, Akio Mori, Masami Taniguchi
Journal: Journal of Allergy and Clinical Immunology (2017)